Clinical Trial Update: A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

View source ↗

Summary

A follow-up study evaluating long-term immunogenicity and safety of NicVAX versus placebo as an aid to smoking cessation has been completed. The sponsor is Nabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• NicVAX (nicotine vaccine)

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Smoking Cessation, Nicotine Dependence | Status: COMPLETED